Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's President and CEO, Bo Cumbo, along with Chief Medical Officer, Dr. Gabriel Brooks, will engage in a fireside chat on Wednesday, September 18, 2024, at 10:20 am ET.
Investors and interested parties can access a live webcast of the fireside chat through the Events page of the Investors section on the company's website. A replay of the webcast will be available for 30 days following the event. Institutional investors seeking meetings with Solid Biosciences management during the conference are advised to contact their Cantor Fitzgerald representatives.
Solid Biosciences Inc. (Nasdaq: SLDB), un'azienda delle scienze della vita focalizzata sullo sviluppo di medicinali genetici di precisione per malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione alla 2024 Cantor Global Healthcare Conference. Il Presidente e CEO dell'azienda, Bo Cumbo, insieme al Direttore Medico, il Dr. Gabriel Brooks, parteciperanno a una chiacchierata informale mercoledì 18 settembre 2024, alle 10:20 ET.
Gli investitori e le parti interessate possono accedere a un webcast in diretta della chiacchierata attraverso la pagina Eventi della sezione Investitori sul sito web dell'azienda. Una registrazione del webcast sarà disponibile per 30 giorni dopo l'evento. Gli investitori istituzionali che desiderano incontrare il management di Solid Biosciences durante la conferenza sono invitati a contattare i loro rappresentanti di Cantor Fitzgerald.
Solid Biosciences Inc. (Nasdaq: SLDB), una empresa de ciencias de la vida centrada en el desarrollo de medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado su participación en la 2024 Cantor Global Healthcare Conference. El Presidente y CEO de la empresa, Bo Cumbo, junto con el Director Médico, Dr. Gabriel Brooks, participarán en una charla informal el miércoles 18 de septiembre de 2024, a las 10:20 a.m. ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la charla a través de la página de Eventos en la sección de Inversionistas del sitio web de la empresa. Una repetición del webcast estará disponible durante 30 días después del evento. Se aconseja a los inversores institucionales que deseen reunirse con la dirección de Solid Biosciences durante la conferencia que contacten a sus representantes de Cantor Fitzgerald.
솔리드 바이오사이언스 주식회사 (Nasdaq: SLDB)는 신경근육 및 심장 질환을 위한 정밀 유전자 의약품 개발에 중점을 둔 생명과학 회사로, 2024 캔토 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 사장 겸 CEO인 보 컴보와 최고 의료 책임자인 가브리엘 브룩스 박사와 함께 2024년 9월 18일 수요일 오전 10시 20분 ET에 대담을 진행할 예정입니다.
투자자 및 관심 있는 각자는 회사 웹사이트의 투자자 섹션 이벤트 페이지를 통해 생중계 웹캐스트에 접속할 수 있습니다. 이벤트 이후 30일 동안 웹캐스트의 재생도 가능합니다. 컨퍼런스 중 솔리드 바이오사이언스 경영진과의 미팅을 원하는 기관 투자자는 캔토 피츠제럴드 대표에게 문의하시기 바랍니다.
Solid Biosciences Inc. (Nasdaq: SLDB), une entreprise des sciences de la vie axée sur le développement de médicaments génétiques de précision pour des maladies neuromusculaires et cardiaques, a annoncé sa participation à la 2024 Cantor Global Healthcare Conference. Le président et PDG de l'entreprise, Bo Cumbo, ainsi que le directeur médical, Dr. Gabriel Brooks, s'engageront dans une discussion informelle mercredi 18 septembre 2024 à 10h20 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la discussion via la page Événements de la section Investisseurs du site Web de l'entreprise. Un replay du webcast sera disponible pendant 30 jours après l'événement. Les investisseurs institutionnels souhaitant rencontrer la direction de Solid Biosciences pendant la conférence sont invités à contacter leurs représentants de Cantor Fitzgerald.
Solid Biosciences Inc. (Nasdaq: SLDB), ein Unternehmen der Lebenswissenschaften, das sich auf die Entwicklung präziser genetischer Medikamente für neuromuskuläre und Herzkrankheiten konzentriert, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Bo Cumbo, wird zusammen mit dem Chief Medical Officer, Dr. Gabriel Brooks, an einem informellen Gespräch am Mittwoch, den 18. September 2024, um 10:20 Uhr ET teilnehmen.
Investoren und Interessierte können über die Event-Seite im Investor-Bereich der Unternehmenswebsite auf ein Live-Webcast des Gesprächs zugreifen. Eine Wiederholung des Webcasts wird 30 Tage nach der Veranstaltung verfügbar sein. Institutionelle Investoren, die während der Konferenz Meetings mit dem Management von Solid Biosciences suchen, sollten sich an ihre Vertreter von Cantor Fitzgerald wenden.
- None.
- None.
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conferences may reach out to their Cantor Fitzgerald representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) participating in the 2024 Cantor Global Healthcare Conference?
Who will represent Solid Biosciences (SLDB) at the 2024 Cantor Global Healthcare Conference?
How can investors access the Solid Biosciences (SLDB) fireside chat at the Cantor conference?
How long will the webcast replay of Solid Biosciences' (SLDB) fireside chat be available?
What type of medicines is Solid Biosciences (SLDB) developing?
